LeuTech partners amend marketing agreement

Article

The $10 million Mallinckrodt agreed in 1999 to pay Palatin Technologies on receipt of FDA approval for its infection-imaging agent LeuTech and attainment of certain sales goals is off the table. A revised agreement between the two companies, announced

The $10 million Mallinckrodt agreed in 1999 to pay Palatin Technologies on receipt of FDA approval for its infection-imaging agent LeuTech and attainment of certain sales goals is off the table. A revised agreement between the two companies, announced May 15, ties the $10 million to a new milestone schedule that has adjusted payments based on LeuTech's anticipated marketing approval and future sales. Mallinckrodt has committed to paying an additional $3.2 million to defray Palatin's expenses, roughly half the expected cost of completing the FDA review process. The money depends on the company meeting certain milestones, although LeuTech was scheduled to receive the first installment of $800,000 before the end of May.

The FDA has raised questions about the initial Biologics License Application for the agent. Palatin executives expect to file an amended application in the second half of this year and hope to gain marketing approval from the FDA in the first half of 2003.

The radiolabeled monoclonal antibody, which binds to white blood cells at the site of an infection, may be especially useful in the diagnosis of equivocal appendicitis. Approximately 320,000 appendectomies are performed annually, according to Palatin. Of these, an estimated 250,000 are equivocal. Of the performed surgeries, a normal appendix is found in about 20% of procedures.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.